Related Experiment Video
Updated: Feb 28, 2026

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
Enhancing CYP3A4 Inhibition Prediction Using a Hybrid GNN-ML Model with Data Augmentation
Somin Woo1,2,3, Ju-Hyeok Jeon4, Sangil Han5
1Graduate School of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
This study developed an AI framework to predict Cytochrome P450 3A4 (CYP3A4) inhibition, crucial for assessing drug-drug interaction risks. The integrated approach combining machine learning and graph neural networks demonstrated improved accuracy and interpretability in metabolic screening.
Area of Science:
- Computational Chemistry
- Pharmacology
- Artificial Intelligence in Drug Discovery
Background:
- Cytochrome P450 3A4 (CYP3A4) is a key enzyme in drug metabolism, affecting 30-50% of marketed drugs.
- Accurate prediction of CYP3A4 inhibition is vital for early identification of potential drug-drug interaction (DDI) risks and toxicity.
- Existing prediction methods require enhancement for improved accuracy and interpretability in drug development pipelines.
Purpose of the Study:
- To evaluate an integrated artificial intelligence (AI) framework for predicting CYP3A4 inhibition percentage.
- To assess the performance of various machine learning (ML) and graph neural network (GNN) models.
- To establish a robust and interpretable framework for metabolic screening and DDI risk assessment.
Main Methods:
- Compiled a large dataset of 23,713 compounds from diverse chemical and public databases.
- Evaluated vector-based ML models (LightGBM, XGBoost, CatBoost, weighted ensemble) and GNN models (O-GNN + CL + Mixup, D-MPNN, GINE, GATv2).
- Employed manifold mixup for GNN training and SMILES enumeration-based test-time augmentation for inference, integrating best models via a weighted ensemble.
Main Results:
- The weighted ML ensemble achieved the highest performance among ML models (RMSE=19.1031, PCC=0.7566).
- The O-GNN + CL + Mixup model showed the best performance among GNNs (RMSE=20.1002, PCC=0.7265).
- The integrated hybrid model demonstrated superior predictive accuracy (RMSE=19.0784, PCC=0.7570) and generalizability upon external validation.
Conclusions:
- Integrating ML and GNN models with data augmentation strategies significantly enhances the robustness and interpretability of CYP3A4 inhibition predictions.
- The developed AI framework provides a practical and effective tool for early-stage metabolic screening.
- This approach facilitates proactive assessment of DDI risks, contributing to safer drug development.
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...